Page 7 - I Mab News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Investment Analysts’ updated eps estimates for Tuesday, May 31st: National Bank Financial assumed coverage on shares of CCL Industries (OTCMKTS:CCDBF). The firm issued an outperform rating on the stock. Intercorp Financial Services (NYSE:IFS) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “Intercorp Financial Services […]

Several brokerages have updated their recommendations and price targets on shares of I-Mab (NASDAQ: IMAB) in the last few weeks: 5/31/2022 – I-Mab was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “I-Mab is a clinical stage biopharmaceutical company. It engages in discovery, development and […]

Brokerages forecast that I-Mab (NASDAQ:IMAB – Get Rating) will announce earnings per share of ($1.11) for the current fiscal quarter, according to Zacks. Zero analysts have issued estimates for I-Mab’s earnings. The company is expected to announce its next quarterly earnings results on Monday, January 1st. On average, analysts expect that I-Mab will report full […]

I-Mab (NASDAQ:IMAB – Get Rating) had its target price reduced by investment analysts at Piper Sandler from $80.00 to $35.00 in a research report issued to clients and investors on Friday, The Fly reports. Piper Sandler’s target price points to a potential upside of 323.22% from the stock’s current price. Other equities analysts also recently […]

/PRNewswire/ -- I-Mab (the "Company") (Nasdaq" IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development and commercialization...